Thursday, June 6, 2024

FDA panel rejects initial MDMA therapy for PTSD

 https://www.ynetnews.com/health_science/article/h1wxtatn0

Key concerns raised by the panel included the study design, potential for drug abuse, risks outweighing benefits, lack of diversity in trials, missing patient data, and potential bias from therapists and facilitators.

1 comment:

  1. One of two possibilities
    1) This is really, really bad because the FDA has a habit of approving anyone on the flimsiest of evidence
    2) The psylocibin folks paid them off

    ReplyDelete

ANONYMOUS COMMENTS WILL NOT BE POSTED!
please use either your real name or a pseudonym.